|
1
|
Klastersky J: Management of fever in
neutropenic patients with different risks of complications. Clin
Infect Dis. 39(Suppl 1): S32–S37. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
González-Barca E, Fernández-Sevilla A,
Carratalá J, Salar A, Peris J, Grañena A and Gudiol F: Prognostic
factors influencing mortality in cancer patients with neutropenia
and bacteremia. Eur J Clin Microbiol Infect Dis. 18:539–544. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Klastersky J, Paesmans M, Rubenstein EB,
Boyer M, Elting L, Feld R, Gallagher J, Herrstedt J, Rapoport B,
Rolston K and Talcott J: The Multinational Association for
Supportive Care in Cancer risk index: A multinational scoring
system for identifying low-risk febrile neutropenic cancer
patients. J Clin Oncol. 18:3038–3051. 2000.PubMed/NCBI
|
|
4
|
Paesmans M: Risk factors assesment in
febrile neutropenia. Int J Antimicrob Agents. 16:107–111. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Kern WV: Risk assesment and risk-based
therapeutic strategies in febrile neutropenia. Curr Opin Infect
Dis. 14:415–422. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ahn S and Lee YS: Predictive factors for
poor prognosis febrile neutropenia. Curr Opin Oncol. 24:376–380.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hui EP, Leung LK, Poon TC, Mo F, Chan VT,
Ma AT, Poon A, Hui EK, Mak SS, Lai M, et al: Prediction of outcome
in cancer patients with febrile neutropenia: A prospective
validation of the multinational association for supportive care in
cancer risk index in a Chinese population and comparison with the
Talcott model and artificial neural network. Support Care Cancer.
19:1625–1635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Glasmacher A, von Lilienfeld-Toal M,
Schulte S, et al: An evidence based evaluation of important aspects
of empirical antibiotic therapy in febrile neutropenic patients.
Clin Microbiol Infect. 11(5): 17–23. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Kern WV: Risk assessment and treatment of
low-risk patients with febrile neutropenia. Clin Infect Dis.
42:533–540. 2006. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Klastersky J, Paesmans M, Georgala A, et
al: Outpatient oral antibiotics for febrile neutropenic cancer
patients using a score predictive for complications. J Clin Oncol.
24:4129–4134. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bow EJ, Rotstein C, Noskin GA, Laverdiere
M, Schwarer AP, Segal BH, Seymour JF, Szer J and Sanche S: A
randomized, open label, multicenter comparative study of the
efficacy and safety of piperacillin-tazobactam and cefepime for the
empirical treatment of febrile neutropenic episodes in patients
with hematologic malignancies. Clin Infect Dis. 43:447–459. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Hughes WT, Armostrong D, Bodey GP, Bow EJ,
Brown AE, Calandra T, Feld R, Pizzo PA, Rolston KV, Shenep JL and
Young LS: 2002 Guidelines for the use of antimicrobial agents in
neutropenic patients with cancer. Clin Infect Dis. 34:730–751.
2002. View
Article : Google Scholar : PubMed/NCBI
|
|
13
|
Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh
MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA and Wingard
JR: Infectious Diseases Society of America: Clinical practice
guideline for the use of antimicrobial agents in neutropenic
patients with cancer: 2010 update by the Infectious Diseases
Society of America. Clin Infect Dis. 52:e56–e93. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Paesmans M: Risk factors assessment in
febrile neutropenia. Int J Antimicrob Agents. 16:107–111. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamana M, Escalante C, Mullen CA,
Frisbee-Hume S and Rolston KV: Bacterial infections in low-risk,
febrile neutropenic patients. Cancer. 104:422–426. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Günalp M, Koyunoğlu M, Gürler S, Koca A,
Yeşilkaya I, Öner E, Akkaş M, Metin Aksu N, Demirkan A, Polat O and
Elhan AH: Independent factors for prediction of poor outcomes in
patients with febrile neutropenia. Med Sci Monit. 20:1826–1832.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zinner SH: Changing epidemiology of
infections in patients with neutropenia and cancer: Emphasis on
gram-positive and resistant bacteria. Clin Infect Dis. 29:490–494.
1999. View
Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wisplinghoff H, Seifert H, Wenzel RP and
Edmond MB: Current trends in the epidemiology of nosocomial
bloodstream infections in patients with hematological malignancies
and solid neoplasms in hospitals in the United States. Clin Infect
Dis. 36:1103–1110. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morris PG, Hassan T, McNamara M, Hassan A,
Wiig R, Grogan L, Breathnach OS, Smyth E and Humphreys H: Emergence
of MRSA in positive blood cultures from patients with febrile
neutropenia - a cause for concern. Support Care Cancer.
16:1085–1088. 2008. View Article : Google Scholar : PubMed/NCBI
|
